Main Industry
Biotechnology
Main Product/Service
We are dedicated to the development of next-generation protein therapeutics. Our expertise lies in protein structural design and synthetic biology, combined with computer simulation and optimization technologies, enabling us to target highly unmet medical needs and develop first-in-class and best-in-class novel drugs for the treatment of various diseases, such as cancer, metabolic diseases, and more.
The content above was translated by Ai
Founded Year
2023
Unified Business No.
94151769
Status
Active
Number of Employees
0
Total Paid-in
Capital
4,984,950 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Protuoso Biosciences is a biotechnology company with pioneering research and development technology, dedicated to developing next-generation multifunctional biologics to treat complex diseases with highly unmet medical needs. By combining its internal proprietary protein engineering technology with a network of top global industry consultants, Protuoso adopts an integrated virtual operating model to effectively reduce the risk assessment time and cost of innovative assets. Protuoso utilizes advanced computational protein design, synthetic biology, and predictive modeling technologies to narrow down design parameters and streamline the drug discovery process, thereby accelerating the development of best-in-class and first-in-class multi-modal therapies. Leveraging its professional protein engineering capabilities and extensive development experience, Protuoso is committed to building an indication-agnostic, diversified pipeline of translational therapies, providing better treatment solutions for patients worldwide.
The content above was translated by Ai
